8-K: Biohaven Announces Positive Phase 3 Trial Results for Troriluzole in Spinocerebellar Ataxia and Provides Third Quarter 2024 Financial Update

Biohaven reports positive topline results for troriluzole in spinocerebellar ataxia, along with third quarter 2024 financial results and pipeline updates.

Summary

• Biohaven announced positive topline results from a pivotal trial of troriluzole for spinocerebellar ataxia (SCA), showing a significant slowing of disease progression.
• The trial met its primary endpoint, demonstrating a statistically significant improvement in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years.
• Troriluzole showed a 50-70% slowing of disease progression, representing a 1.5-2.2 year delay over the 3-year study period.
• The company plans to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2024 for troriluzole to treat all SCA genotypes.
• Biohaven also initiated a Phase 2 trial for BHV-2100 in acute migraine and continues to advance multiple other programs.
• The company completed a public offering of common shares, raising approximately $269.9 million in net proceeds.
• Research and development expenses for the third quarter of 2024 were $157.6 million, compared to $95.5 million in the same period of 2023.
• Biohaven reported a net loss of $160.3 million, or $1.70 per share, for the third quarter of 2024, compared to a net loss of $102.6 million, or $1.50 per share, for the same period in 2023.
• Cash, cash equivalents, marketable securities and restricted cash totaled approximately $642 million as of October 2, 2024.

Sentiment

Score: 8

Explanation: The document is highly positive due to the significant clinical trial success with troriluzole and the strong cash position. The increased R&D spending and net loss are expected for a company in this stage of development, but the overall tone is optimistic.

Positives

• The positive topline results for troriluzole in SCA represent a significant advancement in treating this debilitating disease.
• The company has a strong cash position of approximately $642 million, providing financial flexibility for ongoing research and development.
• The initiation of a Phase 2 trial for BHV-2100 in migraine expands the company's pipeline into a large market.
• The company is advancing multiple programs across various therapeutic areas, including epilepsy, mood disorders, and oncology.
• The successful public offering has strengthened the company's financial position.

Negatives

• The company reported a net loss of $160.3 million for the third quarter of 2024, which is an increase from the $102.6 million loss in the same period of 2023.
• Research and development expenses have increased significantly, reflecting the costs of advancing multiple clinical trials.
• The company's non-GAAP adjusted net loss was $164.1 million, or $1.74 per share, for the third quarter of 2024.

Risks

• The company's success is dependent on the successful development and regulatory approval of its drug candidates.
• Clinical trials may not always yield positive results, and regulatory approvals are not guaranteed.
• The company faces competition from other pharmaceutical companies developing treatments for similar diseases.
• The company's financial performance is subject to fluctuations in research and development expenses and other operating costs.
• The company's forward-looking statements are subject to various risks and uncertainties.

Future Outlook

Biohaven anticipates significant milestones in 2024 and 2025, including NDA submission for troriluzole, topline data from multiple trials, and advancement of its MoDE platform. The company expects to report on a number of updates including SMA topline data and data across its MoDE platform including a SAD/MAD update and multiple INDs spanning 1AR for the potential treatment of dilated cardiomyopathy, galactose deficient IgA for IgA nephropathy and a further optimized IgG degrader for use in rare diseases.

Management Comments

• Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, stated that the team continues to advance multiple late and early stage assets that have the potential to change the current standard of care treatment paradigm across a number of diseases.
• Dr. Coric highlighted the positive topline results in the RWE trial assessing troriluzole for the treatment of spinocerebellar ataxia as a watershed moment for the company.
• Dr. Coric also mentioned the recent initiation of the Phase 2 trial with BHV-2100 in acute migraine and the potential for a highly-effective, non-sedating, non-opioid treatment for pain and migraine.

Industry Context

Biohaven's focus on rare and common diseases aligns with the broader industry trend of developing targeted therapies. The positive results for troriluzole in SCA address a significant unmet need in a disease with no currently approved treatment options. The company's expansion into migraine treatment with BHV-2100 also positions it in a large and competitive market.

Comparison to Industry Standards

• The troriluzole results are particularly notable as there are no approved treatments for SCA, making this a potential first-in-class therapy.
• The use of real-world evidence (RWE) and an external control group from the CRC-SCA is in line with FDA guidance and is a novel approach in this space.
• The company's pipeline includes multiple programs in various therapeutic areas, which is comparable to other large biopharmaceutical companies.
• The increase in R&D spending is consistent with the growth phase of a clinical-stage company, but the net loss is higher than some peers at similar stages.
• The $642 million cash position is strong compared to many other companies of similar size, providing a solid foundation for future development.

Stakeholder Impact

• Shareholders will be impacted by the positive clinical trial results and the successful capital raise.
• Patients with SCA may benefit from the potential approval of troriluzole.
• Employees will be impacted by the company's growth and expansion.
• The company's financial performance will impact its suppliers and creditors.

Next Steps

• Biohaven plans to submit an NDA to the FDA for troriluzole in 4Q 2024.
• The company will continue enrollment in the Phase 2 trial for BHV-2100 in migraine.
• Topline data from the Phase 3 trial with taldefgrobep in SMA is expected in 4Q 2024.
• The company will initiate a Phase 2 trial with taldefgrobep in obesity in 4Q 2024 or early 2025.
• The company will continue to advance its MoDE platform and submit multiple INDs in 2024.
• The company will continue to advance Phase 1 SAD and MAD studies with subcutaneous BHV-1300, with a further study update in 4Q 2024.

Key Dates

Keywords

Troriluzole, Spinocerebellar Ataxia, SCA, BHV-2100, Migraine, Clinical Trials, NDA, R&D, Phase 3, Phase 2, Public Offering, Financial Results, Biopharmaceutical, Neurology, Oncology